SCHIP1

Summary

SCHIP1 (schwannomin interacting protein 1, HGNC:15678) is a protein-coding gene on chromosome 3q25.33, encoding Schwannomin-interacting protein 1 (P0DPB3).

Enables identical protein binding activity. Predicted to be involved in positive regulation of hippo signaling. Predicted to act upstream of or within several processes, including face morphogenesis; fibroblast migration; and luteinization. Located in several cellular components, including cell junction; cytosol; and nuclear body.

Source: NCBI Gene 29970 — RefSeq curated summary.

At a glance

• Gene–disease (curated): complex neurodevelopmental disorder (Limited, GenCC)
• GWAS associations: 23
• Clinical variants (ClinVar): 9 total
• MANE Select transcript: NM_014575

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:15678
Approved symbol	SCHIP1
Name	schwannomin interacting protein 1
Location	3q25.33
Locus type	gene with protein product
Status	Approved
Aliases	SCHIP-1
Ensembl gene	ENSG00000151967
Ensembl biotype	protein_coding
OMIM	619206
Entrez	29970

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 10 protein_coding, 4 retained_intron, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000412423, ENST00000445224, ENST00000460298, ENST00000461058, ENST00000472483, ENST00000475932, ENST00000482804, ENST00000482885, ENST00000483730, ENST00000495954, ENST00000527095, ENST00000638311, ENST00000638749, ENST00000639448, ENST00000640565, ENST00000689690

RefSeq mRNA: 30 — MANE Select: NM_014575 NM_001197107, NM_001197108, NM_001197109, NM_001394282, NM_001394283, NM_001394284, NM_001394285, NM_001394286, NM_001394287, NM_001394288, NM_001394289, NM_001394290, NM_001394291, NM_001394293, NM_001394294, NM_001394295, NM_001394296, NM_001414415, NM_001414416, NM_001414417, NM_001414418, NM_001414419, NM_001414420, NM_001414421, NM_001414422, NM_001414423, NM_001414424, NM_001414425, NM_001414426, NM_014575

CCDS: CCDS3186, CCDS56292, CCDS56293, CCDS56294, CCDS93418, CCDS93419

Canonical transcript exons

ENST00000638749 — 8 exons

Exon	Start	End
ENSE00002216381	159896723	159897359
ENSE00003803208	159273244	159273883
ENSE00004473136	159764443	159765138
ENSE00004475110	159888820	159888943
ENSE00004475117	159886207	159886324
ENSE00004475160	159887708	159887905
ENSE00004475165	159866163	159866281
ENSE00004475169	159892097	159892190

Expression profiles

Bgee: expression breadth ubiquitous, 133 present calls, max score 97.68.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 25.2287 / max 1411.1280, expressed in 1446 samples.

FANTOM5 promoters (28 alternative TSS)

Promoter ID	TPM avg	Samples expressed
39545	8.5892	483
39541	5.2460	1269
39538	1.7921	862
39543	1.6689	328
39547	1.3413	296
39546	1.2330	269
39536	0.9091	468
39548	0.7508	237
39562	0.6784	178
39531	0.6004	78

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	97.68	gold quality
prefrontal cortex	UBERON:0000451	96.42	gold quality
Brodmann (1909) area 9	UBERON:0013540	96.18	gold quality
superior frontal gyrus	UBERON:0002661	95.77	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	95.53	gold quality
frontal cortex	UBERON:0001870	95.52	gold quality
temporal lobe	UBERON:0001871	95.34	gold quality
amygdala	UBERON:0001876	95.30	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	95.24	gold quality
cerebral cortex	UBERON:0000956	95.23	gold quality
Ammon’s horn	UBERON:0001954	95.13	gold quality
gastrocnemius	UBERON:0001388	95.10	gold quality
ganglionic eminence	UBERON:0004023	94.78	gold quality
corpus callosum	UBERON:0002336	94.67	gold quality
muscle of leg	UBERON:0001383	94.58	gold quality
anterior cingulate cortex	UBERON:0009835	94.50	gold quality
primary visual cortex	UBERON:0002436	94.36	gold quality
substantia nigra	UBERON:0002038	94.14	gold quality
right frontal lobe	UBERON:0002810	94.14	gold quality
putamen	UBERON:0001874	93.92	gold quality
skeletal muscle tissue	UBERON:0001134	93.77	gold quality
caudate nucleus	UBERON:0001873	93.49	gold quality
brain	UBERON:0000955	93.04	gold quality
nucleus accumbens	UBERON:0001882	93.04	gold quality
hindlimb stylopod muscle	UBERON:0004252	92.99	gold quality
hypothalamus	UBERON:0001898	92.72	gold quality
heart left ventricle	UBERON:0002084	92.41	gold quality
cortical plate	UBERON:0005343	92.37	gold quality
cerebellum	UBERON:0002037	92.03	gold quality
cerebellar cortex	UBERON:0002129	91.99	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-8271	yes	16.72
E-MTAB-9067	yes	10.99
E-ANND-3	yes	6.37
E-ENAD-27	no	4.46
E-MTAB-9543	no	1.22

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

39 targeting SCHIP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-548AZ-3P	99.82	70.56	3549
HSA-MIR-548BC	99.82	70.61	3524
HSA-MIR-548E-3P	99.82	70.59	3514
HSA-MIR-548F-3P	99.82	70.59	3540
HSA-MIR-139-5P	99.80	69.50	1399
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-548A-3P	99.76	70.58	3524
HSA-MIR-4753-5P	99.54	68.51	1356
HSA-MIR-409-3P	99.50	66.33	1192
HSA-MIR-653-5P	99.46	67.35	1300
HSA-MIR-520F-5P	99.34	70.40	1632
HSA-MIR-130A-5P	99.33	70.26	2623
HSA-MIR-10522-5P	99.26	68.50	2087
HSA-MIR-3191-5P	99.24	66.52	1722
HSA-MIR-3675-3P	99.09	67.70	968
HSA-MIR-140-3P	99.04	67.69	1324

Literature-anchored findings (GeneRIF, showing 4)

• chromosome 3 mapping by in situ hybridization and somatic cell hybrids (PMID:11701967)
• Schip1 associates with the cortical actin cytoskeleton network and modulates its dynamics in response to PDGF signaling via interaction with the Nherf2/ezrin complex. (PMID:25807495)
• SNPs within genes SCHIP1 and PDE8A were associated with measures of facial size in both the GWAS and replication cohorts and passed a stringent genomewide significance threshold adjusted for multiple testing of 34 correlated traits. For both SCHIP1 and PDE8A, we demonstrated clear expression in the developing mouse face by both whole-mount in situ hybridization and RNA-seq (PMID:27560698)
• This is the first report of a SCHIP1/IQCJ-SCHIP1 point mutation in humans associated with a neurological-developmental phenotype (PMID:28787085)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	schip1	ENSDARG00000035175
danio_rerio	SCHIP1	ENSDARG00000038981
mus_musculus	Schip1	ENSMUSG00000027777
rattus_norvegicus	Schip1	ENSRNOG00000009276
drosophila_melanogaster	Schip1	FBGN0032221
caenorhabditis_elegans		WBGENE00018074

Protein

Protein identifiers

Schwannomin-interacting protein 1 — P0DPB3 (reviewed: P0DPB3)

All UniProt accessions (8): P0DPB3, A0A1W2PQT1, A0A1W2PR78, A0A1W2PR91, A0A8I5KTZ3, C9J366, C9JWG6, F8WDG0

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Homooligomer (via coiled coil domain). Interacts with NF2; the interaction is direct. Interacts with ANK3.

Subcellular location. Cytoplasm.

Tissue specificity. Preferentially expressed in brain, skeletal muscles and heart. Also expressed in detected in pancreas, kidney, liver, lung, and placenta.

Similarity. Belongs to the SCHIP1 family.

Isoforms (6)

UniProt ID	Names	Canonical?
P0DPB3-1	SCHIP1-1, SCHIP-1, SCHIP-1a	yes
P0DPB3-2	SCHIP1-2, SCHIP-1-D241/253
P0DPB3-3	SCHIP1-3, SCHIP-1-D22/253
P0DPB3-4	SCHIP1-4
B3KU38-1	IQCJ-SCHIP1-1
B3KU38-2	IQCJ-SCHIP1-2

RefSeq proteins (30): NP_001184036, NP_001184037, NP_001184038, NP_001381211, NP_001381212, NP_001381213, NP_001381214, NP_001381215, NP_001381216, NP_001381217, NP_001381218, NP_001381219, NP_001381220, NP_001381222, NP_001381223, NP_001381224, NP_001381225, NP_001401344, NP_001401345, NP_001401346, NP_001401347, NP_001401348, NP_001401349, NP_001401350, NP_001401351, NP_001401352, NP_001401353, NP_001401354, NP_001401355, NP_055390* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR015649	SCHIP_1_C	Domain
IPR039045	SCHIP_1	Family

Pfam: PF10148

UniProt features (23 total): compositionally biased region 9, region of interest 4, splice variant 4, sequence variant 2, chain 1, modified residue 1, sequence conflict 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P0DPB3-F1	61.13	0.15

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 117

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 207 (showing top): MODULE_52, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, MULLIGHAN_NPM1_SIGNATURE_3_UP, ACTACCT_MIR196A_MIR196B, BROWNE_HCMV_INFECTION_6HR_DN, YAGI_AML_WITH_INV_16_TRANSLOCATION, GENTILE_RESPONSE_CLUSTER_D3, GOBP_HIPPO_SIGNALING, GRAHAM_CML_QUIESCENT_VS_NORMAL_QUIESCENT_DN, MODULE_66, MODULE_118, FOSTER_TOLERANT_MACROPHAGE_UP, SCHMAHL_PDGF_SIGNALING, HESS_TARGETS_OF_HOXA9_AND_MEIS1_UP, HFH4_01

GO Biological Process (12): positive regulation of hippo signaling (GO:0035332), luteinization (GO:0001553), kidney development (GO:0001822), estrogen metabolic process (GO:0008210), female gonad development (GO:0008585), post-embryonic development (GO:0009791), fibroblast migration (GO:0010761), platelet-derived growth factor receptor signaling pathway (GO:0048008), skeletal system morphogenesis (GO:0048705), smooth muscle tissue development (GO:0048745), roof of mouth development (GO:0060021), face morphogenesis (GO:0060325)

GO Molecular Function (2): identical protein binding (GO:0042802), protein binding (GO:0005515)

GO Cellular Component (6): cytoplasm (GO:0005737), plasma membrane (GO:0005886), cell junction (GO:0030054), nucleoplasm (GO:0005654), cytosol (GO:0005829), nuclear body (GO:0016604)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
hippo signaling	1
regulation of hippo signaling	1
positive regulation of intracellular signal transduction	1
female gonad development	1
ovulation cycle process	1
animal organ development	1
renal system development	1
steroid metabolic process	1
hormone metabolic process	1
gonad development	1
development of primary female sexual characteristics	1
multicellular organism development	1
multicellular organismal process	1
ameboidal-type cell migration	1
cell surface receptor protein tyrosine kinase signaling pathway	1
skeletal system development	1
animal organ morphogenesis	1
muscle tissue development	1
anatomical structure development	1
anatomical structure morphogenesis	1
head morphogenesis	1
face development	1
protein binding	1
binding	1
intracellular anatomical structure	1
membrane	1
cell periphery	1
nuclear lumen	1
cytoplasm	1
nucleoplasm	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

60 interactions, top by confidence:

A	B	Type	Score
SCHIP1	SCOC	psi-mi:“MI:0915”(physical association)	0.690
SCOC	SCHIP1	psi-mi:“MI:0915”(physical association)	0.690
SCHIP1	SCHIP1	psi-mi:“MI:0915”(physical association)	0.590
SCHIP1	PSMD4	psi-mi:“MI:0915”(physical association)	0.520
SCHIP1	NF2	psi-mi:“MI:0915”(physical association)	0.400
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
SCOC	SSNA1	psi-mi:“MI:0914”(association)	0.350
SCHIP1	VWA8	psi-mi:“MI:0914”(association)	0.350
FGFR4	SH3PXD2B	psi-mi:“MI:2364”(proximity)	0.270
SCHIP1	ARFGEF1	psi-mi:“MI:0915”(physical association)	0.000
SCHIP1	SCHIP1	psi-mi:“MI:0915”(physical association)	0.000
SCHIP1	TRHDE	psi-mi:“MI:0915”(physical association)	0.000
STRN	SCHIP1	psi-mi:“MI:0915”(physical association)	0.000
DCAF6	SCHIP1	psi-mi:“MI:0915”(physical association)	0.000
SENP6	SCHIP1	psi-mi:“MI:0915”(physical association)	0.000
ZC3H13	SCHIP1	psi-mi:“MI:0915”(physical association)	0.000
FTH1	SCHIP1	psi-mi:“MI:0915”(physical association)	0.000
USP11	SCHIP1	psi-mi:“MI:0915”(physical association)	0.000
NAP1L1	SCHIP1	psi-mi:“MI:0915”(physical association)	0.000
SCHIP1	PSMD4	psi-mi:“MI:0915”(physical association)	0.000
AHSA1	SCHIP1	psi-mi:“MI:0915”(physical association)	0.000
NCAM2	SCHIP1	psi-mi:“MI:0915”(physical association)	0.000
SCHIP1	MAP1B	psi-mi:“MI:0915”(physical association)	0.000
SCHIP1	PBRM1	psi-mi:“MI:0915”(physical association)	0.000
SLC8A1	SCHIP1	psi-mi:“MI:0915”(physical association)	0.000
PTMS	SCHIP1	psi-mi:“MI:0915”(physical association)	0.000
SCHIP1	SLF2	psi-mi:“MI:0915”(physical association)	0.000
SCHIP1	HERC1	psi-mi:“MI:0915”(physical association)	0.000

ESM2 similar proteins: A0A088MLT8, A2AQ25, B3KU38, B5DF41, E9PSK7, O15079, O35274, P0DPB3, P0DPB4, P12755, P49140, P85299, Q0D2I5, Q14DQ1, Q1LY51, Q3B7M3, Q3SYW5, Q4KMA0, Q4R3X1, Q50H33, Q5F3L9, Q5FVG6, Q5RD40, Q5XKK7, Q60698, Q6ZNC4, Q6ZUS6, Q6ZWB6, Q80U23, Q80U62, Q80XA6, Q812A5, Q86YI8, Q8BXL9, Q8K2W6, Q8ND83, Q8NFH8, Q8QFX1, Q8TEK3, Q924W7

Diamond homologs: A0A088MLT8, A8DYY6, B3KU38, P0DPB3, P0DPB4, Q1A5X6, Q8BPW0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

9 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	8
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3243 predictions. Top by Δscore:

Variant	Effect	Δscore
3:159287880:A:T	donor_gain	0.9900
3:159619202:A:AG	acceptor_gain	0.9900
3:159619202:AAT:A	acceptor_gain	0.9900
3:159619202:AATG:A	acceptor_gain	0.9900
3:159664158:A:T	donor_gain	0.9900
3:159764437:CCCTA:C	acceptor_loss	0.9900
3:159764438:CCTA:C	acceptor_loss	0.9900
3:159764441:A:AG	acceptor_gain	0.9900
3:159764441:A:T	acceptor_loss	0.9900
3:159764441:AG:A	acceptor_gain	0.9900
3:159764442:G:GG	acceptor_gain	0.9900
3:159764442:GG:G	acceptor_gain	0.9900
3:159765097:G:GT	donor_gain	0.9900
3:159765139:G:GG	donor_gain	0.9900
3:159273882:GT:G	donor_gain	0.9800
3:159273884:G:GG	donor_gain	0.9800
3:159287845:C:CG	donor_gain	0.9800
3:159462816:TAGA:T	acceptor_gain	0.9800
3:159619203:A:G	acceptor_gain	0.9800
3:159619204:T:TA	acceptor_gain	0.9800
3:159764442:GGA:G	acceptor_gain	0.9800
3:159764442:GGATT:G	acceptor_gain	0.9800
3:159273880:CAGT:C	donor_gain	0.9700
3:159422645:G:GG	donor_gain	0.9700
3:159462815:TTAGA:T	acceptor_gain	0.9700
3:159462817:AGATA:A	acceptor_gain	0.9700
3:159489981:GGGC:G	donor_gain	0.9700
3:159551738:T:G	acceptor_gain	0.9700
3:159764442:GGAT:G	acceptor_gain	0.9700
3:159422640:GTACA:G	donor_gain	0.9600

AlphaMissense

3263 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:159866188:T:A	I338N	1.000
3:159866191:G:C	R339T	1.000
3:159866192:A:C	R339S	1.000
3:159866192:A:T	R339S	1.000
3:159866200:T:C	L342S	1.000
3:159886209:T:C	L370P	1.000
3:159886227:T:C	L376S	1.000
3:159886227:T:G	L376W	1.000
3:159886233:T:A	I378K	1.000
3:159886233:T:C	I378T	1.000
3:159886233:T:G	I378R	1.000
3:159886235:T:C	C379R	1.000
3:159886236:G:A	C379Y	1.000
3:159886237:C:G	C379W	1.000
3:159886238:T:C	F380L	1.000
3:159886239:T:C	F380S	1.000
3:159886239:T:G	F380C	1.000
3:159886240:T:A	F380L	1.000
3:159886240:T:G	F380L	1.000
3:159887802:T:C	L440S	1.000
3:159887807:G:C	A442P	1.000
3:159887813:G:C	A444P	1.000
3:159887814:C:A	A444D	1.000
3:159887822:G:C	A447P	1.000
3:159887826:T:C	L448P	1.000
3:159887828:G:C	A449P	1.000
3:159887834:G:C	A451P	1.000
3:159887835:C:A	A451D	1.000
3:159887846:G:C	A455P	1.000
3:159887847:C:A	A455D	1.000

dbSNP variants (sampled 300 via entrez): RS1000002930 (3:159449555 G>A), RS1000010671 (3:159435969 C>A), RS1000026687 (3:159455329 C>A,G,T), RS1000028369 (3:159827601 C>G,T), RS1000030019 (3:159294394 C>T), RS1000033975 (3:159287622 G>A), RS1000040552 (3:159429068 G>T), RS1000048395 (3:159737896 C>T), RS1000064249 (3:159852977 G>A,C), RS1000064810 (3:159715016 A>C), RS1000066137 (3:159655135 CT>C), RS1000067235 (3:159495213 C>A), RS1000067305 (3:159596737 G>A), RS1000072448 (3:159681897 G>A,C,T), RS1000081586 (3:159742118 C>T)

Disease associations

OMIM: gene MIM:619206 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
complex neurodevelopmental disorder	Limited	Autosomal recessive

Mondo (1): complex neurodevelopmental disorder (MONDO:0100038)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

23 associations (top):

Study	Trait	p-value
GCST000157_2	Celiac disease	1.000000e-09
GCST000337_16	Quantitative traits	8.000000e-07
GCST001850_13	Major depressive disorder	1.000000e-06
GCST003129_8	Primary biliary cholangitis	1.000000e-23
GCST004571_18	Iron status biomarkers (total iron binding capacity)	5.000000e-07
GCST004572_31	Iron status biomarkers (transferrin saturation)	5.000000e-07
GCST004721_15	Congenital heart disease (maternal effect)	3.000000e-06
GCST004721_16	Congenital heart disease (maternal effect)	7.000000e-06
GCST004723_13	Conotruncal heart defects (maternal effects)	8.000000e-06
GCST004723_19	Conotruncal heart defects (maternal effects)	3.000000e-06
GCST005523_17	Celiac disease	1.000000e-08
GCST005523_18	Celiac disease	8.000000e-08
GCST005523_41	Celiac disease	3.000000e-27
GCST005533_2	Limited cutaneous systemic scleroderma	2.000000e-11
GCST005534_12	Systemic sclerosis	9.000000e-06
GCST005534_2	Systemic sclerosis	1.000000e-11
GCST005534_9	Systemic sclerosis	2.000000e-08
GCST006107_2	Upper eyelid morphology	6.000000e-06
GCST006444_2	Bone mineral density (hip)	4.000000e-10
GCST007508_5	Self-reported childhood asthma in adult smokers	2.000000e-07
GCST008489_16	Celiac disease	4.000000e-08
GCST90000032_2	Myeloproliferative neoplasms	8.000000e-11
GCST90002381_193	Eosinophil count	3.000000e-11

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0006334	total iron binding capacity
EFO:1001017	limited scleroderma
EFO:0007702	hip bone mineral density
EFO:0004251	myeloproliferative disorder
EFO:0004842	eosinophil count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases expression, increases mutagenesis	3
bisphenol A	decreases expression	2
Arsenic	affects methylation, increases abundance, increases expression	2
Valproic Acid	affects expression, decreases methylation	2
Cyclosporine	decreases expression, increases methylation	2
pirinixic acid	increases activity, increases expression, affects binding	1
sodium arsenate	increases expression, increases abundance	1
trichostatin A	affects cotreatment, decreases expression	1
afimoxifene	decreases expression, decreases reaction	1
sodium arsenite	affects expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
CGP 52608	affects binding, increases reaction	1
entinostat	decreases expression	1
mesotrione	affects methylation, increases abundance	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	decreases expression	1
(+)-JQ1 compound	decreases expression	1
PCI 5002	affects cotreatment, increases expression	1
Bortezomib	decreases expression	1
Temozolomide	increases expression	1
Acetaminophen	decreases expression	1
Atrazine	decreases expression	1
Cisplatin	increases expression	1
Doxorubicin	increases expression	1
Estrogens	decreases expression, decreases reaction	1
Herbicides	affects methylation, increases abundance	1
Methapyrilene	increases methylation	1
Mitoxantrone	affects response to substance	1

Clinical trials (associated diseases)

2 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT06310681	Not specified	COMPLETED	Pilot Testing of a Co-adapted Group Programme for Parents/Carers of Children With Complex Neurodisability
NCT07303049	Not specified	NOT_YET_RECRUITING	Cognitive Benefit of Intensive Rehabilitation Using Rhythmic Music Training in Children With Complex Neurodevelopmental Disorder